787 results match your criteria Reviews in Cardiovascular Medicine[Journal]


Access to PCSK9 Inhibitors.

Rev Cardiovasc Med 2018 ;19(S1):S47-S50

Departments of Epidemiology & Medicine, University of Iowa College of Public Health and Carver College of Medicine, Iowa City, IA.

View Article

Download full-text PDF

Source
January 2018
6 Reads

PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.

Rev Cardiovasc Med 2018 ;19(S1):S31-S46

Department of Cardiology, University of Chicago Medicine, Chicago, IL.

Low-density lipoprotein (LDL) receptors on the surface of liver hepatocytes are the primary way that humans regulate serum LDL cholesterol levels. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a proteolytic enzyme that indirectly regulates serum LDL cholesterol (LDL-C) by causing the destruction of LDL receptors. Less LDL receptors result in increased LDL-C in the bloodstream but inhibiting or binding the circulating PCSK9 results in increased LDL receptors with the resultant decrease in serum LDL-C. Read More

View Article

Download full-text PDF

Source
January 2018
5 Reads

Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag.

Rev Cardiovasc Med 2018 ;19(S1):S25-S30

Division of Cardiology, Advocate Heart Institute at Advocate Lutheran General Hospital, Park Ridge, IL.

Familial hypercholesterolemia is one of the most common autosomal dominant inherited genetic disorders, yet it is frequently undiagnosed, leading to a markedly increased risk for cardiovascular events. Understanding the pathophysiology of the disease as well as the importance of cascade screening is critical to appropriate treatment of patients. Though the mainstay of therapy for heterozygous familial hypercholesterolemia remains statins, many patients require additional therapy including ezetimibe and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies to achieve adequate low-density lipoprotein cholesterol (LDL-C) lowering. Read More

View Article

Download full-text PDF

Source
January 2018
2 Reads

Can We Cure Atherosclerosis?

Rev Cardiovasc Med 2018 ;19(S1):S20-S24

Department of Cardiology, University of Chicago Medicine, Chicago, IL.

Cardiovascular disease mortality rates have begun to rise in the United States. Based on the large body of supportive evidence, we propose a proof-of-concept, first-in-human trial to cure atherosclerosis: CURing Early ATHEROsclerosis (CURE ATHERO). This trial is based on a model of intensive induction therapy for extensive, if not complete, plaque regression, followed by intermittent maintenance therapy. Read More

View Article

Download full-text PDF

Source
January 2018
2 Reads

Statin Intolerance.

Rev Cardiovasc Med 2018 ;19(S1):S9-S19

Departments of Medicine & Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Statins are critical medications to prevent and treat cardiovascular disease and they are generally very well tolerated. In some instances, however, statin intolerance may limit use of these lifesaving medications. Statin intolerance has many definitions but is commonly diagnosed when a patient is unable to continue statin therapy due to perceived, or objectively documented, adverse effects. Read More

View Article

Download full-text PDF

Source
January 2018
6 Reads

Identifying Patients for Nonstatin Therapy.

Rev Cardiovasc Med 2018 ;19(S1):S1-S8

Departments of Medicine & Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Statins are first-line therapy for reducing atherosclerotic cardiovascular disease (ASCVD) risk. Some patients remain at high ASCVD risk despite maximizing statin therapy. Ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) have been shown to reduce ASCVD events in randomized trials and may be of benefit in selected high-risk patients with cardiovascular disease (CVD) or familial hypercholesterolemia (FH). Read More

View Article

Download full-text PDF

Source
January 2018
5 Reads

Atrioesophageal Fistula Following Radiofrequency Catheter Ablation of Atrial Fibrillation.

Rev Cardiovasc Med 2017 ;18(3):115-122

Department of Cardiovascular Medicine, Beaumont Health, Royal Oak, MI.

Atrioesophageal fistula (AEF) is a rare but catastrophic complication of catheter ablation of atrial fibrillation (AF), with an incidence of 0.03% to 1.5% per year. Read More

View Article

Download full-text PDF

Source
January 2017
18 Reads

Syncope in Young Women: Broadening the Differential Diagnosis.

Rev Cardiovasc Med 2017 ;18(3):100-114

Aurora Medical Center, Milwaukee, WI.

Syncope is defined as a sudden transient loss of consciousness (TLOC) with concomitant loss of postural tone followed by spontaneous recovery. It is a subset of a broader class of medical conditions, including postural orthostatic tachycardia syndrome (POTS), orthostatic hypotension, and neurally mediated syncope (NMS), that may result in TLOC. The overlap of these clinical conditions leads to confusion regarding syncope classification that can hinder evaluation strategies, and pose challenges for diagnosis and treatment, particularly in young women. Read More

View Article

Download full-text PDF

Source
January 2017
9 Reads

A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine.

Rev Cardiovasc Med 2017 ;18(3):93-99

Baylor University Medical Center, Baylor Heart and Vascular Hospital, Baylor Heart and Vascular Institute, Dallas, TX.

With the adoption of the new definition and classification of cardiorenal syndrome (CRS) and its relevant subtypes, much attention has been placed on elucidating the mechanisms of heart and kidney interactions. The pathophysiologic pathways are of great interest by which acute heart failure may result in acute kidney injury (AKI; type 1), chronic heart failure accelerates the progression of chronic kidney disease (CKD; type 2), AKI provokes cardiac events (type 3), and CKD increases the risk and severity of cardiovascular disease (type 4). A remarkable interest has also been placed on the acute and chronic systemic conditions, such as sepsis and diabetes, that simultaneously affect heart and kidney function (type 5). Read More

View Article

Download full-text PDF

Source
January 2017
6 Reads

Two Reports of Quadricuspid Aortic Valve With Aortic Insufficiency.

Rev Cardiovasc Med 2017 ;18(2):88-91

Department of Cardiology, Cork University Hospital, Cork, Ireland.

We report two cases of a quadricuspid aortic valve with severe aortic incompetence. Both patients presented with dyspnea on exertion. Their physical examinations demonstrated wide pulse pressures with diastolic murmurs. Read More

View Article

Download full-text PDF

Source
January 2017
7 Reads

Role of Exogenous Phosphocreatine in Chemotherapy-induced Cardiomyopathy.

Rev Cardiovasc Med 2017 ;18(2):82-87

Section of Cardiology, Republican Clinical Hospital, Kazan, Russia.

The 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) regimen is widely used in the management of breast cancer. The common cardiotoxic effects of doxorubicin include congestive heart failure and left ventricular dysfunction, and those of cyclophosphamide include pericarditis, myocarditis, and congestive heart failure. It has been postulated that cardiotoxicity of 5-fluorouracil presents as coronary artery diseases (eg, angina). Read More

View Article

Download full-text PDF

Source
January 2017
5 Reads

Cardiac Metastasis of Nonvisceral Soft-tissue Leiomyosarcoma.

Rev Cardiovasc Med 2017 ;18(2):78-81

Department of Cardiology, Kaiser Permanente Oakland Medical Center, Oakland, CA; Division of Research, Kaiser Permanente Northern California, Oakland, CA.

Metastasis of a nonvisceral leiomyosarcoma to the heart is rare. We present the case of a man with a history of an upper extremity cancerous lesion that was completely resected with appropriate surveillance monitoring, which then metastasized to the heart 14 years later, presenting as superior vena cava syndrome. Full evaluation found no other metastatic lesions, including no residual sarcoma at the former primary site. Read More

View Article

Download full-text PDF

Source
January 2017
9 Reads

Two Perspectives of the Appropriate Use Criteria in Cardiology Practice: Advantageous and Useful or Limiting and Harmful?

Rev Cardiovasc Med 2017 ;18(2):73-77

University of California, Irvine CA.

The appropriate use criteria (AUC) has become an integral part of the cardiologist's daily practice and have evolved greatly since their inception over a decade ago. However, as health care costs continue to rise, the AUC has come to play an even more pivotal role in the way medicine-specifically cardiology-is practiced today. This editorial describes two opposing viewpoints commonly held by practicing clinicians of the AUC. Read More

View Article

Download full-text PDF

Source
January 2017
10 Reads

Timing of Percutaneous Coronary Intervention and Therapeutic Hypothermia in Patients With ST-Elevation Myocardial Infarction and Out-of-hospital Cardiac Arrest.

Rev Cardiovasc Med 2017 ;18(2):67-72

Department of Cardiology, Lenox Hill Hospital, New York, NY.

The American College of Cardiology/American Heart Association guidelines include a Class 1 recommendation to initiate therapeutic hypothermia (TH) in comatose patients with out-of-hospital cardiac arrest (OHCA) with an initial shockable rhythm who have achieved return of spontaneous circulation. There is also a Class 1 recommendation for immediate angiography in these patients whose initial electrocardiography shows ST-elevation myocardial infarction (STEMI). However, due to a lack of clinical trials evaluating these patients who have received both percutaneous coronary intervention (PCI) and TH, controversy remains regarding whether the two can be safely combined. Read More

View Article

Download full-text PDF

Source
January 2017
6 Reads

Percutaneous Coronary Intervention for Coronary Bifurcation Lesions.

Rev Cardiovasc Med 2017 ;18(2):59-66

Division of Cardiology, UCLA Medical Center, Los Angeles, CA.

Percutaneous coronary intervention (PCI) of lesions at coronary bifurcations poses a technical challenge. Short-term complications, including periprocedural myocardial infarction, and long-term complications such as in-stent restenosis and stent thrombosis, are higher in patients with bifurcation lesions. Techniques for PCI of bifurcation lesions include stenting of the main branch alone, and the use of two or more stents to cover the main and side branches. Read More

View Article

Download full-text PDF

Source
January 2017
5 Reads

Swallowing-induced Supraventricular Tachyarrhythmia.

Rev Cardiovasc Med 2017 ;18(1):53-58

Nerve and Muscle Center of Texas, Houston, TX.

Swallowing-induced supraventricular tachyarrhythmia is an extremely rare entity with unclear pathophysiology. A 55-year-old man presented with a 2-year history of worsening presyncopal symptoms triggered only by drinking liquids of any temperature. Results of a physical examination were unremarkable except for reproducible atrial tachycardias to 180 to 210 beats/minute documented on rhythm strips when the patient was given water to drink. Read More

View Article

Download full-text PDF

Source
January 2017
4 Reads

Spontaneous Coronary Artery Dissection: Insights From Histology and Optical Coherence Tomography.

Rev Cardiovasc Med 2017 ;18(1):44-52

Cedars Sinai Heart Institute, Los Angeles, CA.

Spontaneous coronary artery dissection (SCAD) is a well-known but infrequent cause of acute coronary syndrome (ACS), and often goes unrecognized. Although management of SCAD is, at times, controversial, when a patient presents with ACS, percutaneous coronary intervention (PCI) is frequently necessary. We present a patient with ST-segment elevation myocardial infarction (STEMI) with SCAD that illustrates two important points: use of intracoronary optical coherence tomography to guide PCI, and histologic assessment to provide a unique insight into the etiology of SCAD. Read More

View Article

Download full-text PDF

Source
January 2017
21 Reads

Arrhythmogenic Right Ventricular Dysplasia: An Under-recognized Form of Inherited Cardiomyopathy.

Rev Cardiovasc Med 2017 ;18(1):37-43

Baylor University Medical Center and Baylor Heart and Vascular Hospital, Dallas, TX.

We report a case of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVD) in order to evaluate the course of an under-recognized form of cardiomyopathy with a vast array of clinical manifestations. The patient is a 49-year-old white woman transferred from an outside hospital due to dyspnea and persistent hypoxia. She had a pertinent family history that included a sister who died suddenly in her 30s from unexplained heart failure. Read More

View Article

Download full-text PDF

Source
January 2017
35 Reads

Spontaneous Coronary Artery Dissection: A Review of Pathogenesis, Presentations, Treatment, and Outcomes.

Rev Cardiovasc Med 2017 ;18(1):29-36

Baylor University Medical Center, Division of Cardiology, Dallas, TX; Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX; Texas A&M College of Medicine, Bryan, TX.

Spontaneous coronary artery dissection (SCAD) is a rare cause of acute coronary syndromes and sudden cardiac death. The epidemiology, pathogenesis, and optimal approaches to diagnosis and management are poorly understood. Additionally, SCAD as a syndrome is commonly under-recognized and its prognosis is not well studied. Read More

View Article

Download full-text PDF

Source
January 2017
52 Reads

Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.

Rev Cardiovasc Med 2017 ;18(1):21-28

Baylor University Medical Center, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Baylor Heart and Vascular Institute, Dallas, TX; The Heart Hospital, Plano, TX.

Homozygous familial hypercholesterolemia (HoFH) is an autosomal codominant disorder manifested by high concentrations of total cholesterol and low-density lipoprotein (LDL) cholesterol, and premature cardiovascular disease. Despite conventional lipid-lowering therapy, LDL cholesterol levels remain elevated in patients with HoFH; these patients are considered to be at high risk for cardiovascular events. In 2012-2013, two drugs with novel mechanisms of action were approved by the US Food and Drug Administration for the treatment of HoFH: lomitapide mesylate and mipomersen. Read More

View Article

Download full-text PDF

Source
January 2017
11 Reads

The Role of Nitrates in the Management of Stable Ischemic Heart Disease: A Review of the Current Evidence and Guidelines.

Rev Cardiovasc Med 2017 ;18(1):14-20

VA New England Healthcare System, Massachusetts, Veterans Epidemiology, Research, and Informatics Center (Maveric), Boston, MA.

Coronary artery disease is the leading cause of mortality in the United States and can result in significant morbidity. In particular, stable ischemic heart disease (SIHD) is a condition that affects nearly 9 million individuals in the United States alone, with substantial annual health care costs related to recurrent medical visits and chronic disease management. Nitrates form a cornerstone of SIHD management by reducing myocardial oxygen consumption and increasing exercise capacity by several mechanisms, including increasing epicardial blood flow through vasodilation and decreased vascular resistance, blunting coronary steal, and reducing preload. Read More

View Article

Download full-text PDF

Source
January 2017
40 Reads

Cardiac Contractility Modulation: A Technical Guide for Device Implantation.

Rev Cardiovasc Med 2017 ;18(1):1-13

Medical Department, University of Heidelberg, Mannheim, Germany; German Centre for Cardiovascular Research (DZHK), Mannheim, Germany.

This article provides a technical description of common implant practice for delivery of cardiac contractility modulation (CCM) therapy to heart failure patients. As of September 2016, the authors of this article collectively have been involved with more than 400 system implantations in five medical centers, beginning with the advent of CCM therapy approximately 12 years ago. CCM therapy has been evaluated in a variety of studies, and was shown to be safe and effective and of benefit to patient quality of life and exercise capacity. Read More

View Article

Download full-text PDF

Source
January 2017
5 Reads

Advances in Heart Failure Management: Improving Outcomes With Innovation.

Rev Cardiovasc Med 2017 ;18(S1):S1-S16

Cardiology Division, Massachusetts General Hospital, Boston, MA; Institute for Clinical Research, Boston, MA.

Heart failure (HF) is a chronic and complex disease entity with an enormous morbidity and mortality. Many of the therapies used in the management of HF were developed decades ago, but recently more novel monitoring and therapeutic strategies have emerged. The employment of these strategies may reduce morbidity and mortality in patients with HF. Read More

View Article

Download full-text PDF

Source
January 2017
12 Reads

Myocardial Bridge Complicated by Acute Myocardial Infarction.

Rev Cardiovasc Med 2016 ;17(3-4):149-153

Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA; Division of Cardiology, Atlanta Veterans Affairs Medical Center, Decatur, GA.

Typically, myocardial bridging (MB) is considered a relatively benign condition; however, serious complications such as angina pectoris, myocardial infarction (MI), and sudden cardiac death may occur. The diagnosis and appropriate treatment of this pathology are important. We report a case of acute anterior wall ST-elevation MI occurring as a complication of MB involving the mid segment of the left anterior descending artery in a young, otherwise healthy woman who underwent a primary stenting procedure. Read More

View Article

Download full-text PDF

Source
October 2018
5 Reads

Utility of Procalcitonin for Diagnosis of Superimposed Infections in Patients With Acute Heart Failure.

Rev Cardiovasc Med 2016 ;17(3-4):144-148

Servicio de cardiología, Universitat de Valencia, Valencia, Spain.

Respiratory infections are well-known precipitant factors for heart failure decompensations. Nevertheless, the diagnosis of life-threatening infections, such as pneumonia, is challenging. Pneumonia and acute heart failure often display overlapping clinical findings and, in other cases, more accurate infection-related findings are missing. Read More

View Article

Download full-text PDF

Source
October 2018
3 Reads

An Unusual Presentation of Native Valve Endocarditis Caused by .

Rev Cardiovasc Med 2016 ;17(3-4):140-143

Department of Internal Medicine, University of Missouri Kansas City, Kansas City MO.

is a coagulase-negative staphylococcal (CoNS) bacterium. It is a common saprophyte on human skin, present in approximately 50% of the healthy adult population; it has emerged as a cause of serious infection in the past two decades. In most cases, there is a predisposing condition, such as a new implant or surgical procedure, before the identification of as the pathogen. Read More

View Article

Download full-text PDF

Source
October 2018
16 Reads

Rotational Atherectomy in a Dissected Coronary Artery That Propagated Into the Sinus of Valsalva: Is This the Last Hope?

Rev Cardiovasc Med 2016 ;17(3-4):137-139

Royal Glamorgan Hospital, Llantrisant, United Kingdom.

Percutaneous coronary intervention (PCI) of a resistant, undilatable lesion can result in coronary dissection. Retrograde propagation of a dissection flap into the sinus of Valsalva is a rare phenomenon. It is commonly seen at the time of PCI to a right coronary artery (RCA) and is associated with potentially fatal consequences. Read More

View Article

Download full-text PDF

Source
October 2018
12 Reads
1.180 Impact Factor

Cardiac Manifestations of Adrenal Insufficiency.

Rev Cardiovasc Med 2016 ;17(3-4):131-136

Division of Cardiovascular Diseases, Carilion Clinic and Virginia Tech Carilion School of Medicine, Roanoke, VA.

It is estimated that the prevalence of primary adrenal insufficiency (Addison disease) is 1 in 10,000 people. There are multiple case reports and several studies that suggest a correlation between Addison disease and abnormalities of cardiac function. The pathophysiology of cardiac abnormalities in this condition is incompletely understood. Read More

View Article

Download full-text PDF

Source
October 2018
5 Reads

Radiofrequency Coils and Pulse Sequences for Cardiac Magnetic Resonance Applications: New Perspectives and Future Developments.

Rev Cardiovasc Med 2016 ;17(3-4):124-130

Institute of Clinical Physiology, National Council of Research, Pisa, Italy.

Cardiac magnetic resonance (CMR) is a relevant diagnostic tool for the evaluation of cardiac morphology, function, and mass. The assessment of myocardial tissue content through the measurement of longitudinal (T1) and transversal (T2) relaxation properties and the development of different technical advances are important clinical novelties of CMR. Recently, magnetic resonance spectroscopy has been explored for the assessment of the metabolic state of tissue for cardiac function evaluation by using nuclei other than protons, such as C and Na, expanding our knowledge of the kinetics of metabolic processes. Read More

View Article

Download full-text PDF

Source
October 2018
5 Reads

An Overview of Pharmacotherapy in Hypertrophic Cardiomyopathy: Current Speculations and Clinical Perspectives.

Rev Cardiovasc Med 2016 ;17(3-4):115-123

Cardiomyopathies Center, First Cardiology Department, AHEPA Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Its clinical course is variable, ranging from a benign asymptomatic or mildly symptomatic course throughout life, to severe symptoms (dyspnea, angina, palpitations) or cardiovascular events (syncope and thromboembolism). Sudden cardiac death (SCD) remains the most striking manifestation of the disease, affecting a minority of patients. Read More

View Article

Download full-text PDF

Source
October 2018
57 Reads

The Role of Novel Cardiorenal Biomarkers in the Cardiac Catheterization Laboratory for the Detection of Acute Kidney Injury.

Rev Cardiovasc Med 2016 ;17(3-4):100-114

Department of Medicine, Division of Cardiology, University of Texas Health Science Center at San Antonio, San Antonio, TX.

Contrast-induced nephropathy related to cardiac and peripheral vascular procedures is a major problem in the United States and abroad. Measures to prevent and treat this complication have been hampered by the lack of clinical tools to detect acute kidney injury following contrast administration. Emerging novel serum and urinary biomarkers may provide sensitive detection of early kidney injury prior to creatinine elevation and allow for more precise risk stratification and management of patients. Read More

View Article

Download full-text PDF

Source
October 2018
5 Reads

ST-segment Elevation: Myocardial Infarction or Simulacrum?

Rev Cardiovasc Med 2016 ;17(3-4):85-99

Aurora Cardiovascular Services, St. Luke's Medical Center, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI.

A rapid diagnosis of ST-segment elevation myocardial infarction (STEMI) is mandatory for optimal treatment of an acute coronary syndrome. However, a small number of patients with suspected STEMI are afflicted with other medical conditions. These medical conditions are rare, but important clinical entities that should be considered when evaluating a STEMI alert. Read More

View Article

Download full-text PDF

Source
October 2018
39 Reads

Utility of Dobutamine Stress Echocardiography in Cardiac Risk Stratification of Patients Undergoing Orthotopic Liver Transplantation.

Rev Cardiovasc Med 2017 ;18(4):146-154

3Division of Cardiology, Department of Internal Medicine, Albert Einstein Medical Center, Philadelphia, PA.

Cardiovascular diseases are a major cause of morbidity and mortality in patients after orthotopic liver transplantation (OLT). This review includes major original articles published in the English-language literature of patients who underwent dobutamine stress echocardiography (DSE) before OLT for cardiac risk stratification. Of a total of 10 original articles (total 1699 patients undergoing DSE), 6 studies used DSE to predict major adverse cardiac events (MACE) in patients undergoing OLT and 4 reported the role of DSE in coronary artery disease (CAD) prediction in patients with end-stage liver disease. Read More

View Article

Download full-text PDF

Source
January 2017
17 Reads

Hyperuricemia and Cardiovascular Disease.

Rev Cardiovasc Med 2017 ;18(4):134-145

Baylor University Medical Center, Dallas, TX; Baylor Heart and Vascular Hospital, Dallas, TX; Bylor Heart and Vascular Institute, Dallas, TX.

Uric acid (UA), the metabolic mediator of gout and urate renal stones, is associated with increased cardiovascular risk burden. Hyperuricemia is a common metabolic disorder, and interaction among UA and cardiovascular diseases has been clearly described. Several illnesses, including hypertension, myocardial infarction, metabolic syndrome, and heart failure, are related to increases in UA levels. Read More

View Article

Download full-text PDF

Source
January 2017
16 Reads

A Focused Review on the Pathophysiology, Diagnosis, and Management of Cardiac Amyloidosis.

Rev Cardiovasc Med 2017 ;18(4):123-133

Columbia University Division of Cardiology, Mount Sinai Heart Institute, Miami Beach, FL.

Amyloidosis is a systemic disorder that results from abnormal protein metabolism, producing amyloid fibrils that are subsequently deposited within vital organs. Cardiac involvement is typically associated with the specific subtypes of immunoglobulin lightchain, transthyretin, secondary amyloidosis, and dialysis-related amyloidosis. The hallmark of cardiac amyloidosis is the development of restrictive cardiomyopathy and heart failure, usually with a preserved left ventricular ejection fraction. Read More

View Article

Download full-text PDF

Source
January 2017
22 Reads

Nutritional Deficiencies and Sarcopenia in Heart Failure: A Therapeutic Opportunity to Reduce Hospitalization and Death.

Rev Cardiovasc Med 2016 ;17 Suppl 1:S30-S39

Abbott Nutrition, Inc, Columbus, OH.

There is an expanding prevalence pool of heart failure (HF) due to the increasing prevalence of survivors of myocardial infarction, diabetes, hypertension, chronic kidney disease, and obesity. There is increasing interest in the role of nutrition in all forms of HF, given observations concerning micro- and macronutrient deficiencies, loss of lean body mass or sarcopenia, and their relationships with hospitalization and death. This review examines the relationships among loss of lean body mass, macro- and micronutrient intake, and the natural history of HF, particularly in the elderly, in whom the risks for all-cause rehospitalization, infection, falls, and mortality are increased. Read More

View Article

Download full-text PDF

Source
June 2017
7 Reads

A Treatment Approach for Patients With Chronic Systolic Heart Failure.

Rev Cardiovasc Med 2016 ;17 Suppl 1:S22-S29

Department of Medicine, Cardiology Division, University of California-San Diego, La Jolla, CA.

The treatment of heart failure with reduced ejection (HFrEF) is changing rapidly. Advances over the past several decades have focused on blocking the adverse effects of neurohormonal activation. This approach has resulted in marked improvement in outcomes in the HFrEF population. Read More

View Article

Download full-text PDF

Source
June 2017
2 Reads

Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management.

Rev Cardiovasc Med 2016 ;17 Suppl 1:S9-S21

Cedars-Sinai Heart Institute, Los Angeles, CA.

Hyperkalemia is a common electrolyte disorder associated with life-threatening cardiac arrhythmias and increased mortality. Patients at greatest risk for hyperkalemia include those with diabetes and those with impaired renal function in whom a defect in the excretion of renal potassium may already exist. Hyperkalemia is likely to become more common clinically because angiotensin receptor blockers and angiotensin-converting enzyme inhibitors are increasingly being used in higher doses and are thought to confer cardiovascular and renal protection. Read More

View Article

Download full-text PDF

Source
June 2017
15 Reads

Heart Failure University 2015: Presentation Summaries.

Authors:

Rev Cardiovasc Med 2016 ;17 Suppl 1:S1-S8

View Article

Download full-text PDF

Source
September 2018
3 Reads

Isolated Left Ventricular Noncompaction Cardiomyopathy: A Transient Disease?

Rev Cardiovasc Med 2016;17(1-2):80-84

Columbia University Division of Cardiology at the Mount Sinai Heart Institute, Miami Beach, FL.

Isolated left ventricular noncompaction is either a distinct cardiomyopathy or a morphologic trait shared by several different types of cardiomyopathies. Although there is no current gold standard for its diagnosis, cardiac imaging is the most commonly accepted modality. Described is a case of left ventricular noncompaction that resolved 2 years after the initial diagnosis. Read More

View Article

Download full-text PDF

Source
June 2017
4 Reads

Vascular Complications of Percutaneous Transradial Cardiac Catheterization.

Rev Cardiovasc Med 2016;17(1-2):76-79

East Carolina Heart Institute, Greenville, NC.

The percutaneous transradial approach for coronary angiography and percutaneous coronary intervention is increasing in the United States. Although its vascular safety profile is better than the traditional femoral approach, it is important to learn about potential complications. In this article, we present two cases of vascular complications, namely, pseudoaneurysm and radial artery occlusion, after transradial cardiac catheterization, along with a review of the relevant literature. Read More

View Article

Download full-text PDF

Source
June 2017
3 Reads

Forty Years of Chest Pain: A Case Report and Contemporary Review of the Diagnostic and Therapeutic Options for Myocardial Bridging.

Rev Cardiovasc Med 2016;17(1-2):69-75

Cedars-Sinai Heart Institute, Los Angeles, CA.

A 48-year-old woman with 40 years of intermittent squeezing chest pain presented with worsening symptoms. Results of an ambulatory electrocardiogram, echocardiogram, and exercise treadmill were unremarkable. Persistent symptoms prompted a computed tomography coronary angiogram (CTCA) that revealed mid-left anterior descending artery myocardial bridging (MB) that was not physiologically significant by exercise single-photon emission CT. Read More

View Article

Download full-text PDF

Source
June 2017
16 Reads

Leading the Way: Cardiology and the Future of HealthTech Innovation.

Rev Cardiovasc Med 2016;17(1-2):67-68

Harbor-UCLA Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
June 2017
11 Reads

An Update From the California Chapter of the American College of Cardiology Board of Directors.

Authors:
Norman E Lepor

Rev Cardiovasc Med 2016;17(1-2):65-66

President, California Chapter of the American College of Cardiology; David Geffen School of Medicine at UCLA and Cedars-Sinai Medical Center, Los Angeles, CA, and Westside Medical Associates of Los Angeles, Beverly Hills, CA.

View Article

Download full-text PDF

Source
June 2017
7 Reads

The Role of Cardiac Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy.

Rev Cardiovasc Med 2016;17(1-2):57-64

Cardiology and Interventional Cardiology Unit, Ospedali Riuniti Marche Nord, Pesaro, Italy.

Until recently, the only imaging technique for the diagnosis and management of hypertrophic cardiomyopathy (HCM) was two-dimensional echocardiography, and the use of cardiac magnetic resonance imaging (cMRI) was limited to patients with poor acoustic windows. Now, cMRI has gained an essential role in the diagnosis of HCM, providing superior visualization of myocardial hypertrophy-even in remote zones of the left ventricle-and visualization of subtle changes in thickness and contractility over time. The morphologic accuracy of cMRI allows for the differentiation of HCM from other pathologic conditions with hypertrophic phenotype. Read More

View Article

Download full-text PDF

Source
June 2017
10 Reads

Cardiovascular Effects of Altitude on Performance Athletes.

Rev Cardiovasc Med 2016;17(1-2):49-56

Lenox Hill Hospital, New York, NY.

Altitude plays an important role in cardiovascular performance and training for athletes. Whether it is mountaineers, skiers, or sea-level athletes trying to gain an edge by training or living at increased altitude, there are many potential benefits and harms of such endeavors. Echocardiographic studies done on athletes at increased altitude have shown evidence for right ventricular dysfunction and pulmonary hypertension, but no change in left ventricular ejection fraction. Read More

View Article

Download full-text PDF

Source
June 2017
93 Reads

A Review of the Clinical Subgroup Analyses From the RE-LY Trial.

Rev Cardiovasc Med 2016;17(1-2):40-48

University of Pittsburgh Medical Center, Heart and Vascular Institute, and Pittsburgh Veterans Administration Medical Center, Department of Cardiology, Pittsburgh, PA.

Dabigatran was the first direct-acting oral anticoagulant approved by the US Food and Drug Administration for prevention of stroke and systemic embolism in people with atrial fibrillation, based on data from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Over 18,000 patients with nonvalvular atrial fibrillation and a moderate-to-high risk of thromboembolic stroke were randomized to warfarin or dabigatran. With respect to the primary endpoints for efficacy and safety, dabigatran was superior to warfarin in the prevention of stroke and thromboembolism and noninferior with respect to major bleeding. Read More

View Article

Download full-text PDF

Source
June 2017
6 Reads

The Role of Medical Therapy in Moderate to Severe Degenerative Mitral Regurgitation.

Rev Cardiovasc Med 2016;17(1-2):28-39

Cedars-Sinai Heart Institute, Los Angeles, CA.

Mitral regurgitation (MR) is a common valvular disorder that has important health and economic consequences. Standardized guidelines exist regarding when and in whom to perform mitral valve surgery, but little information is available regarding medical treatment of MR. Many patients with moderate or severe MR do not meet criteria for surgery or are deemed to be at high risk for surgical therapy. Read More

View Article

Download full-text PDF

Source
June 2017
12 Reads

Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia.

Rev Cardiovasc Med 2016;17(1-2):16-27

Oregon Health and Science University, Portland, OR.

Familial hypercholesterolemia (FH) is an autosomal co-dominant disorder marked by extremely high low-density lipoprotein (LDL) cholesterol levels and concomitant premature vascular disease. FH is caused by mutations that most commonly affect three genes integrally involved in the LDL receptor's ability to clear LDL particles from the circulation. Primary intervention efforts to lower LDL cholesterol have centered on therapies that upregulate the LDL receptor. Read More

View Article

Download full-text PDF

Source
June 2017
16 Reads

A Closer Look at Fractional Flow Reserve in Complex Anatomic Subsets: Left Main Disease, Bifurcation Lesions, and Saphenous Vein Grafts.

Rev Cardiovasc Med 2016;17(1-2):7-15

University of California, Irvine and VA Long Beach, Irvine, CA.

Fractional flow reserve (FFR) is a well-validated tool for determining the functional significance of a coronary artery stenosis, facilitating clinical decisions regarding the need for revascularization. FFR-guided revascularization improves clinical and economic outcomes. However, its application remains challenging in certain complex anatomic subsets, including left main coronary artery stenosis, bifurcation disease, and saphenous vein graft disease. Read More

View Article

Download full-text PDF

Source
June 2017
4 Reads